Literature DB >> 6454435

Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann's thrombasthenia type I and type II.

H Lee, A T Nurden, A Thomaidis, J P Caen.   

Abstract

We have studied the fibrinogen binding to the platelets of four type I thrombasthenic two type II thrombasthenic patients and 15 normal subjects. The amount of [125I]fibrinogen bound to washed platelets in the presence or absence of 10 micrometers ADP was measured and the results expressed as the percentage of the total radioactivity added. The mean value for specific binding to the platelets of normal subjects was 3.7 (range 1--7.25) at 15 min after the addition of ADP. Type I thrombasthenic patients lack glycoproteins (GP) IIb and IIIa in the platelet membrane and intra-platelet fibrinogen. In all four patients studied, little or no specific fibrinogen binding was detected. Platelets of type II thrombasthenic patients contain detectable, although markedly reduced amounts of GP IIb and IIIa, and subnormal or normal levels of fibrinogen. In these platelets, significant specific fibrinogen binding was observed, the values being slightly below or at the lower end of the normal range. Fibrinogen binding to normal platelets was also measured after the addition of an IgG purified from the serum of a multi-transfused thrombasthenic type I patient. This antibody was previously shown to be directed against the GP IIb/IIIa complex as located by crossed immunoelectrophoresis. Specific fibrinogen-binding was blocked and the extent of the inhibition was directly proportional to the concentration of the antibody added.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454435     DOI: 10.1111/j.1365-2141.1981.00047.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia.

Authors:  M H Ginsberg; A Lightsey; T J Kunicki; A Kaufmann; G Marguerie; E F Plow
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.

Authors:  S R Hanson; F I Pareti; Z M Ruggeri; U M Marzec; T J Kunicki; R R Montgomery; T S Zimmerman; L A Harker
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 3.  Platelets in allergy. Assays and interpretation.

Authors:  M Joseph
Journal:  Clin Rev Allergy       Date:  1988

4.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

Review 5.  Glanzmann's thrombasthenia.

Authors:  M S Tullu; P S Dixit; S B Nair; J R Kamat; R K Vaswani; S D Shetty; A R Pawar
Journal:  Indian J Pediatr       Date:  2001-06       Impact factor: 1.967

6.  von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia.

Authors:  L De Marco; A Girolami; T S Zimmerman; Z M Ruggeri
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

7.  Antiplatelet antibodies in cases of Glanzmann's thrombasthenia with and without a history of multiple platelet transfusion.

Authors:  Kanjaksha Ghosh; B Kulkarni; S Shetty; S Nair
Journal:  Indian J Hum Genet       Date:  2009-01

8.  A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane.

Authors:  A T Nurden; J P Rosa; D Fournier; C Legrand; D Didry; A Parquet; D Pidard
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.

Authors:  G DiMinno; F Coraggio; A M Cerbone; A M Capitanio; C Manzo; M Spina; P Scarpato; G M Dattoli; P L Mattioli; M Mancini
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

10.  Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.

Authors:  G Di Minno; A M Cerbone; P L Mattioli; S Turco; C Iovine; M Mancini
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.